Waleed Siddiqi, MD
Nephrology · Tuscaloosa, ALNPI 1538124771
Payments from drug & device makers
Across 125 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$463
- AstraZeneca$367
- OPKO Pharmaceuticals, LLC$350
- Vifor Pharma, Inc.$242
- Otsuka America Pharmaceutical, Inc.$232
- Bayer$140
- plus $736 from 16 others
What the payments were for
- Food & beverage$2,530100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 18 | $463 |
| AstraZeneca(2 entities) | 20 | $367 |
| OPKO Pharmaceuticals, LLC | 24 | $350 |
| Vifor Pharma, Inc. | 10 | $242 |
| Otsuka America Pharmaceutical, Inc. | 12 | $232 |
| Bayer | 6 | $140 |
| GSK | 6 | $107 |
| Calliditas Therapeutics US Inc. | 4 | $91 |
| Amgen(2 entities) | 5 | $86 |
| Fresenius USA Marketing, Inc. | 3 | $59 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| Novartis | 2 | $53 |
| Ardelyx, Inc. | 2 | $52 |
| Travere Therapeutics, Inc. | 2 | $49 |
| Axogen | 1 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
How this compares
$2,530 in reported general payments places this provider in the 45th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 18 | $8,867 |
| ProsolParenteral Amino Acid 20% No.1 | 22 | $3,743 |
| Bumetanide | 57 | $1,425 |
| Doxazosin Mesylate | 92 | $1,109 |
| Cinacalcet Hcl | 24 | $1,101 |
| Hydralazine Hcl | 54 | $859 |
| Amlodipine Besylate | 94 | $717 |
| Chlorthalidone | 36 | $465 |
| Terazosin Hcl | 24 | $401 |
| Potassium Chloride | 11 | $302 |
| Tamsulosin Hcl | 48 | $267 |
| Metoprolol Succinate | 40 | $257 |
| Nifedipine ErNifedipine | 21 | $223 |
| Midodrine Hcl | 11 | $218 |
| Furosemide | 56 | $159 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Tuscaloosa
- David TietjenHuntsville$2.6M
- Dana RizkBirmingham$2.6M
- Michael QuadriniHuntsville$1.3M
- Eric WallaceBirmingham$1.3M
- David BainsHuntsville$856K
- Michal MrugBirmingham$793K
- Phillip MadoniaAlabaster$475K
- Carlo CastilloHuntsville$461K
- Sumeet MunjalMontgomery$191K
- Gaurav AgarwalBirmingham$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.